Table 1.

Clinical Outcomes Following HIV Health Care Transition in the Medical Literature.

Study [Ref] (Region)	Population	Median age at Transfer (years)	Post-HCT Retention	Post-HCT cART Adherence	Post-HCT HIV Suppression	Post-HCT CD4 Change	Post-HCT Mortality
Maturo, 2015 [17] (US)	N=38 BA-HIV	NA	18 (47%) completed transfer to adult careb	NA	NA	NA	NA
Fish, 2014 [60] (UK)	N=14, PA-HIV	17	NA	At transfer: 64% taking HAART At death: 36% taking HAART	14% with documented suppression at last evaluation	At transfer: median CD4: 120 cells/uL At death: median CD4: 27 cells/uL	100% (by study design)
Ryscavage, 2016 [42] (US)	N=50 19 PA-HIV 31-BA-HIV	24.5	50%a	NA	Pre-transfer: 36% Post-transfer: 57% (p=NS)	Pre-transfer: 347 cells/uL Post-transfer: 351 cells/uL	0%
Hope, 2016 [61] (UK)	N=211 PA-HIV	17.6	88%	NA	Pre-transfer: 43% Post-transfer: 63% (p=<.001)	Pre-transfer: 450 cells/uL Post-transfer: 420 cells/uL *Rate of decline decreased post transfer	4.3%
Righetti, 2015 [62] (Italy)	N=45	8.8	84%b	NA	Post-transfer: 73%	NA	NA
Kakkar, 2016 [59] (Canada)	N=45 PA-HIV (25 consented to study)	18	76%c	60% reported less than “excellent” adherence	Pre-transfer: 60%	Pre-transfer: CD4>500 cells/uL: 41%Post-transfer: CD4>500 cells/uL: 29%	8.9%
Weijsenfeld, 2016 [11] (Netherlands)	N=59 78% PA-HIV 7% BA-HIV 12% unknown	18.8	86% Mean missed appts increased from 0.2/yr to 0.3/yr after HCT (p<.001)	NA	NA	NA	NA
Westling, 2016 [10] (Sweden)	34 91% PA-HIV	19	NA	Pre-transfer: 88% prescribed HAART	Pre-transfer: 90% Post-transfer: 92%	NA	NA

PA-HIV: perinatally-acquired HIV; BA-HIV: behaviorally acquired HIV; HAART: Highly active antiretroviral therapy; HCT: health care transition

^aRetention was defined as the completion of at least two visits over 12 months following linkage to adult care.

^bDefinition of post-HCT not defined.

^cRetention was defined as at least one physician visit within 6 months of the interview.